The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.
A. Fabi
No relevant relationships to disclose
M. Russillo
No relevant relationships to disclose
G. Metro
No relevant relationships to disclose
P. Papaldo
No relevant relationships to disclose
C. Nisticò
No relevant relationships to disclose
G. Ferretti
No relevant relationships to disclose
F. Cuppone
No relevant relationships to disclose
G. D'Auria
No relevant relationships to disclose
D. Giannarelli
No relevant relationships to disclose
F. Cognetti
No relevant relationships to disclose